DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for cardiofaciocutaneous syndrome 1 — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCardiofaciocutaneous syndrome 1 maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cardiofaciocutaneous syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KRas proto-oncogene, GTPase (KRAS) — KRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gnpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7VVB · 1.7 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER (GNP). Experimental structure, not a prediction.
What the evidence adds up to
Cardiofaciocutaneous syndrome is a RASopathy with facial, cardiac, and ectodermal abnormalities, but no pathognomonic or obligatory clinical traits have been established. A 2002 paper proposed a clinical scoring method called the CFC index to confirm the diagnosis and differentiate the condition from Noonan and Costello syndromes while molecular studies were still in progress. A 2013 report described fetal autopsy findings in a 17-week fetus with a novel BRAF mutation, noting potential similarities and differences with the postnatal presentation, but the extent of phenotypic expression in affected fetuses remained unclear.
A 2020 paper on anaesthetic management of a paediatric patient with cardiofaciocutaneous syndrome noted that musculoskeletal abnormalities such as muscle weakness and decreased muscle mass are observed in all RASopathies but are particularly prominent in this syndrome. Important considerations for anaesthesiologists include evaluating for possible cardiac defects, anticipating potentially difficult airway management, and considering respiratory muscle weakness. The authors suggested that desflurane and remifentanil may aid faster recovery and reduce the risk of respiratory complications after general anaesthesia because of their rapid metabolism or elimination.
No drug treatment for the syndrome itself is described in any of these abstracts. The 2002 paper explicitly stated that controversy existed concerning the delineation of the syndrome and that no traits were pathognomonic or obligatory. The 2013 report was limited to a single fetus. The 2020 paper addressed only perioperative anaesthetic management, not any disease-modifying therapy.
What is still missing are any clinical trials of drug treatments for cardiofaciocutaneous syndrome, any molecularly targeted therapies tested in patients, and any systematic natural history studies that could inform trial design or patient stratification.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 2002 · 79 citations · open access
CFC index for the diagnosis of cardiofaciocutaneous syndrome
AbstractControversy exists concerning the delineation of cardiofaciocutaneous syndrome (CFC). Many authors have attempted to establish syndrome traits for CFC, but to date none are pathognomonic or obligatory. We have created a clinical and objective method, called the CFC index, for CFC diagnosis. This method also differentiates CFC from Noonan syndrome and Costello syndrome, CFC's main differential diagnosis. We propose the use of the CFC index for the confirmation of CFC diagnosis and to differentiate CFC from other phenotypically similar genetic conditions, while molecular studies are still in progress.
Pediatric and Developmental Pathology · 2013 · 4 citations
Fetal Autopsy Findings of Cardiofaciocutaneous Syndrome with a Unique <i>BRAF</i> Mutation
AbstractCardiofaciocutaneous (CFC) syndrome is a RASopathy phenotypically characterized by facial, cardiac, and ectodermal abnormalities. The extent to which this phenotype is expressed in the affected fetus is unclear, and a better understanding of the fetal autopsy findings in CFC syndrome could facilitate diagnosis and understanding of the developmental effects of dysregulated BRAF activity. Here we describe the fetal autopsy findings in a case of CFC syndrome in a 17-week fetus with a novel BRAF mutation that demonstrates potential similarities and differences with the postnatal presentation of CFC syndrome.
Anesthesia Progress · 2020 · 2 citations · open access
Anesthetic Management of a Pediatric Patient With Cardiofaciocutaneous Syndrome
AbstractCardiofaciocutaneous (CFC) syndrome is a rare condition characterized by congenital heart disease, craniofacial dysmorphology, and dermatological abnormalities. CFC syndrome is one of the RASopathies, a family of syndromes that also includes Noonan and Costello syndromes, all with underlying gene mutations involving the Ras/mitogen-activated protein kinase pathways. Important considerations for anesthesiologists caring for these patients include the need to evaluate for possible cardiac defects, anticipating and planning for potentially difficult airway management, and the consideration of potential weakness of the respiratory muscles. Musculoskeletal abnormalities, such as muscle weakness and decreased muscle mass, are observed in all RASopathies, but are particularly prominent in CFC syndrome. In patients with CFC syndrome who experience respiratory muscle weakness, the use of desflurane and remifentanil may aid in a faster recovery and effectively help reduce the risk of respiratory complications, such as respiratory depression, following general anesthesia because of their rapid metabolism or elimination.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
